Mucormycosis During Second Wave Of COVID-19 in India: Exploratory Analysis From Tertiary Care Centre Of Uttar Pradesh


  • Akhil Pratap Singh Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
  • Manish Kumar Bansal Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
  • Vikas Kumar Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
  • Geetu Singh Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
  • Manoj Kumar Sarojini Naidu Medical College, Agra, Uttar Pradesh, India



Mucormycosis, COVID‐ 19, Corticosteroids, Diabetes, India, Rhizopus


Background: In April and May 2021, India faced massive second wave of COVID-19 pandemic and then became the hotspots of mucormycosis across globe. Hence, we planned the first analysis of mucormycosis in Uttar Pradesh. Aim and Objectives: coThe objectives were to explore the epidemiology, vaccination status, clinical features, microbiological findings, treatment of mucormycosis and outcome. Material and Methods: This was an observational study of mucormycosis at tertiary care centre of Agra, Uttar Pradesh, India from 20 May 2021 to 15 July 2021. Results: 98 patients’ data with mucormycosis was analyzed. Patients had median age of 55 years. COVID-19 infection was present in 69.4% of participants and diabetes mellitus was present as underlying co-morbid condition in more than 85% of patients. 91.8 % of cases were unvaccinated with steroid consumption in almost 60% of patients. R. arrhizus was among the most common agent while we found less commonly reported fungi like R.homothallicus, Apophysomyces, Cunninghamella. 41.8% of cases were successfully treated and 16.3% of cases expired. Conclusion: Diabetes mellitus was labeled as major predisposing factor and most patients were unvaccinated. Awareness about fungal infections, rigorous monitoring of chronic diseases, judicious use of drugs, early diagnosis and prompt treatment is decisive for better outcome.


Download data is not yet available.


Ministry of Health and Family Welfare, Government of India. Available from:, accessed on 25/12/2021.

Raut A, Huy TN. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet 2020; 21: 265-4 . S2213-2600 (21)00265-4

The Economic Times. Over 45,000 cases of mucormycosis reported in India: Health ministry tells Rajya Sabha. Available from:, accessed on 25/12/2021.

Bala K, Chander J, Handa U, Punia RS, Attri AK et al. A prospective study of mucormycosis in north India: Experience from a tertiary care hospital. Med Mycol 2015; 53 :248-57. ?doi: 10.1093/mmy/myu086.PMID: 25587084.[Pubmed]

Patel A, Kaur H, XessI ,Michael, J.S, Savio J, Rudramurthy S, et al. ?A multi-centre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. ?Microbiol. Infect. 2020, 26, 944.e9–944.e15. ?doi: 10.1016/j.cmi.2019.11.02.PMID: 31811914.[Pubmed]

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol 2021; 69:244-52.doi: 10.4103/ijo.IJO_3774_20 .PMID: 33463566.[Pubmed]

Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021; 69:1670-92. doi:10.4103/ijo.IJO_1565_21

Prakash H, Chakrabarti, A. Epidemiology of Mucormycosis in India. Microorganisms 2021;9:523. doi: 10.3390/microorganisms9030523.PMID: 33806386.[Pubmed]

Banerjee S, Denning DW, Chakrabarti A. One Health aspects & priority roadmap for fungal diseases: A mini-review. Indian J Med Res 2021; 153: 311-319.doi: 10.4103/ijmr.IJMR_768_21. PMID: 33906993.[Pubmed]

Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes MetabSyndr 2021;185. 34192610.

Mehta S, Pandey A. Rhino?orbital mucormycosis associated with COVID?19. Cureus 2020; 12(9) :10726. doi:10.7759/cureus.10726

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from:, accessed on 25/12/2021.

Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries. Available from:, accessed on 25/12/2021.?

Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. MucoCovi Network. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis 2021; 15(9). doi: 10.3201/eid2709.210934. PMID: 34087089

Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, Mohanan AA, et al. A case series of invasive mucormycosis in patients with COVID- 19 infection. Int J Otorhinolaryngol Head Neck Surg 2021; 7: 867-70., Posted on: 28 JUN 2021, 2:48PM by PIB Delhi, accessed 25/12/2021

Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 71 :2459-68. doi: 10.1093/cid/ciaa530.PMID: 32358954.[Pubmed]

Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, etal. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021; 186 :289–98.doi: 10.1007/s11046-021-00528-2.PMID: 33544266.[Pubmed]

Revannavar SM,?P S S, Samaga L, et al. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021; 14 :e241663.doi: 10.1136/bcr-2021-241663.PMID: 33906877.[Pubmed]

Xu H, Zhong L, Deng J. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020; 12 :8. doi:10.1038/s41368-020-0074-x

StoneN, Gupta N, Schwartz I . Mucormycosis: time to address this deadly fungal infection. Lancet 2021; 5247(21): 00148-8. S2666-5247(21)00148-8

Jeong W, Keighley C, Wolfe R, et al., The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports, Clin. Microbiol. Infect 2019; 25 : 26–34. doi: 10.1016/j.cmi.2018.07.011.PMID: 30036666.[Pubmed]

Skiada, A.; Pavleas, I.; Drogari-Apiranthitou, M. Epidemiology and Diagnosis of Mucormycosis: An Update. J. Fungi 2020; 6 : 265.doi: 10.3390/jof6040265.PMID: 33147877.[Pubmed]

John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel) 2021; 7(4) :298. doi: 10.3390/jof7040298.PMID: 33920755.[Pubmed]

John TM, Jacob CN, KontoyiannisDP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi 2021; 7 :298. ?

Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19 a meta-analysis. JAMA 2020; 324(13):1330–13341. doi: 10.1001/jama.2020.17023.PMID: 32876694.[Pubmed]

Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well- controlled diabetic patient. Med Mycol Case Rep. 2020 ; 29(1) :22-24. doi: 10.1016/j.mmcr.2020.05.008. PMID: 32547914.[Pubmed]

Mulakavalupil B, Vaity C, Joshi S, Misra A, Pandit RA, Absence of Case of Mucormycosis (March 2020–May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit, Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021, doi: h ps:// dsx.2021.06.006.

Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev. 2020; 19 :102564.doi: 10.1016/j.autrev.2020.102564. PMID: 32376396.[Pubmed]

Smith HW, Kirchner JA Cerebral mucormycosis: A report of 3 cases. Arch Otolaryng (Chicago) 1950; 68: 715-726.doi: 10.1001/archotol.1958.00730020739010.PMID: 13593957.[Pubmed]

Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol 2021; 69 :1563-8.?25. doi: 10.4103/ijo.IJO_310_21.PMID: 34011742.[Pubmed]

Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J LaryngolOtol 2021; 135 :442-7.?doi: 10.1017/S0022215121000992.PMID: 33827722.[Pubmed]

Song G, Liang G, Liu W. Fungal co?infections associated with global COVID?19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia 2020; 31:1?8. doi: 10.1007/s11046-020-00462-9.PMID: 32737747.[Pubmed]




How to Cite

Singh AP, Bansal MK, Kumar V, Singh G, Kumar M. Mucormycosis During Second Wave Of COVID-19 in India: Exploratory Analysis From Tertiary Care Centre Of Uttar Pradesh. Indian J Community Health [Internet]. 2021 Dec. 31 [cited 2024 Apr. 23];33(4):640-6. Available from:



Original Article